AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12117401 — intervention group
Group type: EXPERIMENTAL
Intervention: Underpowered clinical trials
Number of subjects: 0
Study 12117401 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis of small studies
Number of subjects: 0
Study 12117401 — intervention group
Group type: EXPERIMENTAL
Intervention: Small trials for rare diseases
Number of subjects: 0
Study 12117401 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-phase trials for drug/device development
Number of subjects: 0
Study 10721069 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 16
Study 10721069 — intervention group
Group type: COMPARATOR
Intervention: Control group (epileptics with comparable clinical characteristics and treatment)
Number of subjects: 16
Study 8628336 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyprenoic acid (600 mg daily)
Number of subjects: 89
Study 8628336 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 8628336 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyprenoic acid
Number of subjects: 89
Study 1735251 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm Elevation (AE) for 2 min
Number of subjects: 22
Study 1735251 — intervention group
Group type: COMPARATOR
Intervention: Arm Lowering (AD) for 2 min
Number of subjects: 22
Study 6398724 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum perineal stimulation (MPS) using monophasic square wave pulses under anaesthesia
Number of subjects: 107
Study 6398724 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MPS)
Number of subjects: 107
Study 6398724 — intervention group
Group type: COMPARATOR
Intervention: Both groups (treatment and control)
Number of subjects: 107
Study 31119695 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal dilator strip applied at bedtime for 28 days
Number of subjects: 70
Study 31119695 — intervention group
Group type: COMPARATOR
Intervention: Nasal dilator strip applied during nasal resistance phase (n=37)
Number of subjects: 70
Study 28762058 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic common bile duct exploration
Number of subjects: 210
Study 28762058 — intervention group
Group type: EXPERIMENTAL
Intervention: Open common bile duct exploration
Number of subjects: 210
Study 28762058 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic retrograde cholangiopancreatography
Number of subjects: 210
Study 26513008 — intervention group
Group type: EXPERIMENTAL
Intervention: MM‐HIIT
Number of subjects: 28
Study 26513008 — intervention group
Group type: COMPARATOR
Intervention: Row‐HIIT
Number of subjects: 28
Study 23606339 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (6 exercises, 3 sets, 20 repetitions at 40-50% of 1RM)
Number of subjects: 44
Study 23606339 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 44
Study 23606339 — intervention group
Group type: COMPARATOR
Intervention: Control (40 min of rest)
Number of subjects: 44
Study 21556366 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 90 mg/m²
Number of subjects: 223
Study 21556366 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel 200 mg/m²
Number of subjects: 223
Study 18236144 — intervention group
Group type: EXPERIMENTAL
Intervention: Large mug book
Number of subjects: 0
Study 18236144 — intervention group
Group type: COMPARATOR
Intervention: Small mug book
Number of subjects: 0
Study 18236144 — intervention group
Group type: COMPARATOR
Intervention: No mug book
Number of subjects: 0
Study 18193118 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG 4000 (Forlax)
Number of subjects: 100
Study 18193118 — intervention group
Group type: COMPARATOR
Intervention: PEG 3350 (Movicolon)
Number of subjects: 100
Study 15039009 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPh)
Number of subjects: 0
Study 15039009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11227034 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant formula with enzymatic degradation of phytic acid
Number of subjects: 10
Study 11227034 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant formula with native phytic acid content (Fe:ascorbic acid ratio 1:2.1)
Number of subjects: 10
Study 11227034 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant formula with native phytic acid content (Fe:ascorbic acid ratio 1:4.2)
Number of subjects: 10
Study 8403307 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 5 mg
Number of subjects: 0
Study 8403307 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 10 mg
Number of subjects: 0
Study 8403307 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 25 mg
Number of subjects: 0
Study 8403307 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 75 mg
Number of subjects: 0
Study 8403307 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 150 mg
Number of subjects: 0
Study 8403307 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (all doses)
Number of subjects: 0
Study 8403307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3948045 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl-oxygen (fentanyl-O2)
Number of subjects: 14
Study 3948045 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl-nitrous oxide/oxygen (fentanyl-N2O/O2)
Number of subjects: 14
Study 28547924 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-mm thin individually customized insole (CI-Core®) with synthetic textile material on the upper side
Number of subjects: 21
Study 28547924 — intervention group
Group type: COMPARATOR
Intervention: No insoles
Number of subjects: 21
Study 28547924 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-mm thin individually customized insole (CI-Core®)
Number of subjects: 21
Study 26955605 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate peel extract (PPE) mouthrinse
Number of subjects: 50
Study 26955605 — intervention group
Group type: COMPARATOR
Intervention: 0.2% chlorhexidine mouthrinse
Number of subjects: 50
Study 25271180 — intervention group
Group type: EXPERIMENTAL
Intervention: Child Life (CL)
Number of subjects: 113
Study 25271180 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital Clowning (HC)
Number of subjects: 113
Study 25271180 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 113
Study 23545917 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate foam, 0.05%
Number of subjects: 125
Study 23545917 — intervention group
Group type: COMPARATOR
Intervention: Vehicle foam
Number of subjects: 125
Study 20878622 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma OPN
Number of subjects: 239
Study 20878622 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum OPN
Number of subjects: 239
Study 20878622 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects and BRD patients)
Number of subjects: 239
Study 18251598 — intervention group
Group type: EXPERIMENTAL
Intervention: Microabrasion with 50 microm of aluminum silicate for 5 seconds followed by bonding with Scotchbond Multipurpose Plus Bonding Adhesive
Number of subjects: 52
Study 18251598 — intervention group
Group type: COMPARATOR
Intervention: Bonding without microabrasion using the same bonding protocol
Number of subjects: 52
Study 17091571 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot tonsillectomy techniques (including diathermy)
Number of subjects: 0
Study 17091571 — intervention group
Group type: COMPARATOR
Intervention: Traditional cold-steel dissection with packs or ties
Number of subjects: 0
Study 14520444 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-gemcitabine (CG)
Number of subjects: 240
Study 14520444 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin-gemcitabine (EG)
Number of subjects: 240
Study 14520444 — intervention group
Group type: COMPARATOR
Intervention: Control (CG)
Number of subjects: 240
Study 14520444 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Life (QOL)
Number of subjects: 240
Study 11881693 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral transmucosal fentanyl citrate (OTFC)
Number of subjects: 33
Study 11881693 — intervention group
Group type: COMPARATOR
Intervention: Placebo oralet
Number of subjects: 33
Study 8694203 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 0 mg
Number of subjects: 80
Study 8694203 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 1 mg
Number of subjects: 80
Study 8694203 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 2 mg
Number of subjects: 80
Study 8694203 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 4 mg
Number of subjects: 80
Study 1597911 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepaid care (capitated health plans)
Number of subjects: 739
Study 1597911 — intervention group
Group type: COMPARATOR
Intervention: Fee-for-service care
Number of subjects: 739
Study 3758361 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-operative radiotherapy (IOR) with doses of 28 to 35 Gy using electron beams
Number of subjects: 101
Study 3758361 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 101
Study 31070113 — intervention group
Group type: EXPERIMENTAL
Intervention: Running speed measured at three different positions (Fo, Ti, Lu) on a treadmill at speeds between 8 and 18 km/h.
Number of subjects: 18
Study 31070113 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement at the L4‐L5 lumbar (Lu) position.
Number of subjects: 18
Study 31070113 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement at the centre of gravity of the tibia (Ti) position.
Number of subjects: 18
Study 31070113 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement on the dorsal surface of the right foot (Fo) position.
Number of subjects: 18
Study 31070113 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact zone measurement points.
Number of subjects: 18
Study 29481324 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal Electrical Stimulation (AG)
Number of subjects: 61
Study 29481324 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal Electrical Stimulation (CG)
Number of subjects: 61
Study 29481324 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PG)
Number of subjects: 61
Study 27644589 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab plus prompt laser treatment
Number of subjects: 340
Study 27644589 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab plus deferred laser treatment
Number of subjects: 340
Study 27644589 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab ± laser therapy
Number of subjects: 340
Study 23967839 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counselling for mothers during the first year of life
Number of subjects: 307
Study 23967839 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 307
Study 23967839 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 307
Study 24236174 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity-Interval Training (HIT)
Number of subjects: 30
Study 24236174 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate Intensity-Continuous Training (MCT)
Number of subjects: 30
Study 24236174 — intervention group
Group type: COMPARATOR
Intervention: Control (CTL)
Number of subjects: 30
Study 24236174 — intervention group
Group type: EXPERIMENTAL
Intervention: HIT and MCT
Number of subjects: 30
Study 21477691 — intervention group
Group type: EXPERIMENTAL
Intervention: 90-mm Reddy female condom in Los Angeles
Number of subjects: 50
Study 21477691 — intervention group
Group type: EXPERIMENTAL
Intervention: 90-mm Reddy female condom in Pune
Number of subjects: 50
Study 21477691 — intervention group
Group type: COMPARATOR
Intervention: Control group (150 mm and 120 mm condoms)
Number of subjects: 50
Study 19654255 — intervention group
Group type: COMPARATOR
Intervention: 2 percent lidocaine with 1:100,000 epinephrine (L100)
Number of subjects: 18
Study 19654255 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 percent bupivacaine with 1:200,000 epinephrine (B200)
Number of subjects: 18
Study 19654255 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 percent prilocaine with 1:200,000 epinephrine (P200)
Number of subjects: 18
Study 19654255 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 percent articaine with 1:200,000 epinephrine (A200)
Number of subjects: 18
Study 19654255 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 percent mepivacaine without vasoconstrictor (Mw/o)
Number of subjects: 18
Study 19654255 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 percent articaine with 1:100,000 epinephrine (A100)
Number of subjects: 18
Study 16723360 — intervention group
Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy (PPV)
Number of subjects: 23
Study 16723360 — intervention group
Group type: COMPARATOR
Intervention: Systemic corticosteroid and/or immunosuppressive treatment
Number of subjects: 23
Study 15319022 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (1.25-2.5 mg/day starting dose, titrated to a mean of 14.5 mg/day by trial end)
Number of subjects: 10
Study 15319022 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (treatment group)
Number of subjects: 10
Study 15319022 — intervention group
Group type: COMPARATOR
Intervention: Placebo (during 2-week run-in phase)
Number of subjects: 10
Study 11148857 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilidine/naloxone solution (25 mg, 50 mg, 100 mg)
Number of subjects: 18
Study 11148857 — intervention group
Group type: COMPARATOR
Intervention: Tilidine/naloxone solution (4 x 50 mg tilidine)
Number of subjects: 18
Study 11148857 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilidine/naloxone retard tablets (50 mg, 100 mg, 200 mg tilidine/tablet)
Number of subjects: 18
Study 9489119 — intervention group
Group type: EXPERIMENTAL
Intervention: Talc slurry (5 g in 50 mL saline)
Number of subjects: 26
Study 9489119 — intervention group
Group type: COMPARATOR
Intervention: Bleomycin (1 mg/kg in 50 mL saline)
Number of subjects: 26
Study 8405501 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (ENX) 4200 anti factor Xa IU once daily
Number of subjects: 233
Study 8405501 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH) 7500 IU twice daily
Number of subjects: 233
Study 8405501 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall incidence of PDVT after aortic surgery
Number of subjects: 233
Study 3543577 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose heparin-DHE
Number of subjects: 259
Study 30092205 — intervention group
Group type: EXPERIMENTAL
Intervention: Trigger point (TrP) release massage
Number of subjects: 25
Study 30092205 — intervention group
Group type: COMPARATOR
Intervention: Sham ultrasound (US) treatment
Number of subjects: 25
Study 28002415 — intervention group
Group type: EXPERIMENTAL
Intervention: Puberty education alone
Number of subjects: 1124
Study 28002415 — intervention group
Group type: EXPERIMENTAL
Intervention: Reusable sanitary pads alone
Number of subjects: 1124
Study 28002415 — intervention group
Group type: EXPERIMENTAL
Intervention: Puberty education and reusable sanitary pads
Number of subjects: 1124
Study 28002415 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 1124
Study 24191286 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose angiotensin II infusion (1 ng/kg per minute) and captopril administration (25 mg×1)
Number of subjects: 4
Study 24191286 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose angiotensin II infusion (3 ng/kg per minute)
Number of subjects: 4
Study 24191286 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldosterone infusion (0.7 µg/kg per hour)
Number of subjects: 4
Study 24191286 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (50 mg/daily) for 6 weeks
Number of subjects: 4
Study 24191286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 23034336 — intervention group
Group type: EXPERIMENTAL
Intervention: Proclear multifocal toric contact lens (CL)
Number of subjects: 20
Study 23034336 — intervention group
Group type: COMPARATOR
Intervention: Proclear toric single vision distance CL (DCL) combined with reading spectacles
Number of subjects: 20
Study 20376430 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX)
Number of subjects: 30
Study 20376430 — intervention group
Group type: COMPARATOR
Intervention: Propofol (PRO)
Number of subjects: 30
Study 20376430 — intervention group
Group type: EXPERIMENTAL
Intervention: Difference in change of ACE score between DEX versus PRO
Number of subjects: 30
Study 18568185 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose indapamide (1.5 mg sustained release daily) with added perindopril
Number of subjects: 73
Study 16380704 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum ghrelin levels in MS patients (n=40)
Number of subjects: 40
Study 16380704 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals, n=20)
Number of subjects: 40
Study 12435173 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (Aranesp) at doses < 1.5 microg/kg
Number of subjects: 0
Study 12435173 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (Aranesp) at doses 1.5 to 2.25 microg/kg
Number of subjects: 0
Study 12435173 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (Aranesp) at doses > 2.25 microg/kg
Number of subjects: 0
Study 12435173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10612884 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention including video scenarios and discussions coordinated by health personnel, aimed at promoting consistent condom use.
Number of subjects: 0
Study 10612884 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study 8942774 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening with faecal-occult-blood tests every 2 years for 10 years
Number of subjects: 137485
Study 8942774 — intervention group
Group type: COMPARATOR
Intervention: Control group (unscreened)
Number of subjects: 137485
Study 8942774 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening group
Number of subjects: 137485
Study 8942774 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 137485
Study 1826911 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (2.5, 5, 7.5, or 10 mg BID)
Number of subjects: 170
Study 1826911 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study 7059544 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate amniotomy
Number of subjects: 68
Study 7059544 — intervention group
Group type: COMPARATOR
Intervention: Retaining membranes intact until full dilatation
Number of subjects: 68
Study 31831388 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy plus standard medical therapy
Number of subjects: 131
Study 31831388 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy alone
Number of subjects: 131
Study 31093922 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression Stockings (CS)
Number of subjects: 20
Study 31093922 — intervention group
Group type: COMPARATOR
Intervention: No Compression Stockings (Control)
Number of subjects: 20
Study 27625142 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg
Number of subjects: 1453
Study 27625142 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 1453
Study 27625142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1453
Study 27625142 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 1453
Study 25808577 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy plus repeated botulinum toxin A (BoNT‐A/OT)
Number of subjects: 20
Study 25808577 — intervention group
Group type: COMPARATOR
Intervention: Occupational therapy alone
Number of subjects: 20
Study 24269485 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizanidine
Number of subjects: 10
Study 24269485 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen
Number of subjects: 10
Study 24269485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 22970914 — intervention group
Group type: EXPERIMENTAL
Intervention: bFGF treatment (direct application of bFGF drops in the clinic and repeated daily by the patient, n = 53)
Number of subjects: 104
Study 22970914 — intervention group
Group type: COMPARATOR
Intervention: Control (spontaneous healing, n = 51)
Number of subjects: 104
Study 22970914 — intervention group
Group type: EXPERIMENTAL
Intervention: bFGF treatment (n = 53)
Number of subjects: 104
Study 19176965 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) 3,000 mg daily
Number of subjects: 0
Study 19176965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16688629 — intervention group
Group type: EXPERIMENTAL
Intervention: Almotriptan 12.5 mg
Number of subjects: 255
Study 16688629 — intervention group
Group type: COMPARATOR
Intervention: Zolmitriptan 2.5 mg
Number of subjects: 255
Study 15560807 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP and metronidazole (400 mg t.i.d. for 10 days)
Number of subjects: 44
Study 15560807 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP and weekly professional supragingival plaque removal for three months (PC)
Number of subjects: 44
Study 15560807 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP, metronidazole, and professional cleaning (PC)
Number of subjects: 44
Study 15560807 — intervention group
Group type: COMPARATOR
Intervention: SRP and placebo
Number of subjects: 44
Study 11159875 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg PRU
Number of subjects: 40
Study 11159875 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg PRU
Number of subjects: 40
Study 11159875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9228354 — intervention group
Group type: EXPERIMENTAL
Intervention: BDP 84 (336 microg/d)
Number of subjects: 423
Study 9228354 — intervention group
Group type: EXPERIMENTAL
Intervention: BDP 42 (336 microg/d)
Number of subjects: 423
Study 9228354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 423
Study 9228354 — intervention group
Group type: EXPERIMENTAL
Intervention: HD BDP 84 (1,344 microg/d)
Number of subjects: 423
Study 8427323 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Group (E)
Number of subjects: 814
Study 8427323 — intervention group
Group type: COMPARATOR
Intervention: Control Group (C)
Number of subjects: 814